H.C. Wainwright analyst Debjit Chattopadhyay raised his price target for uniQure to $48 with all the patients successfully dosed in the dose-confirmation study of AMT-061. With all patients now successfully dosed in the dose-confirmation study of AMT-061 and a previously disclosed six to eight weeks follow-up, the stage is now set for the company to unveil top-line data and confirm dosing for its Phase III HOPE-B pivotal study, which is on schedule by year end 2018, Chattopadhyay tells investors in a research note. He keeps a Buy rating on uniQure.